STAT1 expression is not required for polyp formation in min mice

Molecular Carcinogenesis

Volumn 47, Issue 2, 2008, Pages 75-79

  Liddle, Forrester J ^a,b   Frank, David A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Colon cancer; Colon polyps; Signal transduction; Transcription factors; Tumorigenesis

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; FERTILITY; GENOTYPE; HETEROZYGOTE; INTESTINE POLYP; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR LOCALIZATION;

ANIMALS; COLONIC POLYPS; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

ANIMALIA; MUS;

EID: 38949115284     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20371     Document Type: Article

References (21)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-1299.
2. Klein B, Zhang XG, Yang LZ, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-874.
3. Barut B, Chauhan D, Uchiyama H, Anderson KC. Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J Clin Invest 1993;92:2346-2352.
4. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large cell lymphoma. J Clin Oncol 1995;13:575-582.
5. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995;55:590-596.
6. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-4639.
7. Lu C, Vickers MF, Kerbel RS. Interleukin-6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992;89:9215-9219.
8. Brown TJ, Roe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 1991;147:2175-2180.
9. Shirota K, LeDuy L, Yuan SY, Jothy S. Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol 1990;58:303-308.
10. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling. Immunity 2004;21:491-501.
11. Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217-220.
12. Yuan H, Liddle FJ, Mahajan S, Frank DA. IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. Carcinogenesis 2004; 25:2247-2255.
13. Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta-Rev Cancer 1997;1332:F25-F48.
14. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-324.
15. Yamada Y, Hata K, Hirose Y, et al. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 2002;62:6367-6370.
16. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-450.
17. Meraz MA, White JM, Sheehan KCF, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity of the JAK-STAT signaling pathway. Cell 1996;84:431-442.
18. Shuai K, Stark GR, Kerr IM, Darnell JE, Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-g. Science 1993;261:1744-1746.
19. Muller M, Laxton C, Briscoe J, et al. Complementation of a mutant cell line: Central role of the 91-kDa polypeptide of ISGF-3 in the interferon-a and -g signal transduction pathway. EMBO J 1993;12:4221-4228.
20. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95: 7556-7561.
21. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.